Tumstatin

Mechanism of Action

• Binds integrin alphavbeta3 on proliferating endothelial cells, inhibiting cap-dependent mRNA translation via mTOR/4E-BP1 axis
• Reduces eIF4E availability for translation initiation, globally suppressing endothelial protein synthesis
• Induces apoptosis via caspase-3 activation without affecting quiescent (non-proliferating) endothelial cells
• Does not inhibit endothelial migration at doses that block proliferation (distinct mechanism from endostatin)
• FAK/Akt dephosphorylation downstream of alphavbeta3 disengagement drives pro-apoptotic signaling

Research Findings

• Tumstatin inhibited tumor growth in multiple mouse xenograft models including melanoma, colon, and lung tumors
• Tumstatin knockout mice (Col4a3-/-, Alport syndrome model) show elevated tumor angiogenesis, confirming endogenous suppressor role
• Anti-proliferative effect requires intact alphavbeta3 binding domain (aa54-132); truncation abolishes activity
• Combination with endostatin showed additive anti-tumor effects in preclinical models targeting complementary endothelial mechanisms
• Tumstatin levels reduced in plasma of patients with aggressive cancers; potential biomarker

Research Protocols

• Mouse tumor models: 0.5-5 mg/kg SC or IP injection of recombinant tumstatin daily or every 48 hours
• In vitro proliferation assay: 10-1000 nM to assess translation inhibition in endothelial cells
• Short peptide T3 (aa54-132): smaller active domain fragment used in research to reduce production cost
• No approved clinical protocols; investigational research only

Interactions

• Endostatin: additive anti-angiogenic effect (complementary binding domains and mechanisms)
• mTOR inhibitors: may overlap mechanistically; combination may cause additive translational suppression in endothelium
• Collagenase/MMP-9: required for in vivo generation from collagen IV basement membrane

Safety Profile

Investigational. No human dosing data. Well tolerated in rodent studies at anti-tumor doses. Alport syndrome patients lacking Col4a3 (and hence tumstatin) show increased cancer susceptibility, reinforcing its protective role.

Legal & Regulatory

Research use only